Royalty Pharma(RPRX) - 2022 Q2 - Earnings Call Presentation

Financial Performance - Adjusted Cash Receipts increased by 10% to $524 million in Q2 2022[10, 15] - Adjusted EBITDA also grew by 10% to $480 million in Q2 2022[10, 15] - Adjusted Cash Flow increased by 12% to $482 million, or $079 per share, in Q2 2022[15] - The company is raising full-year Adjusted Cash Receipts guidance to $2275 million - $2350 million, reflecting approximately 7% to 10% year-over-year growth[10, 58] Portfolio and Transactions - Year-to-date transactions announced total $25 billion, including $17 billion upfront payments[10] - Royalty Pharma acquired an upward tiering 65%-10% royalty on Trelegy sales, expecting at least $200 million to Adjusted Cash Receipts in 2025[26] - The company acquired Blueprint Medicines' royalty on Gavreto for up to $340 million, with high-teens to mid-twenties percent royalty on annual sales outside the United States, excluding Greater China[34] Biohaven Acquisition - Pfizer's acquisition of Biohaven is expected to accelerate Royalty Pharma's returns on common and preferred equity[10, 36] - Royalty Pharma is entitled to milestones of up to 19 to 295x funded amount of $250 million related to zavegepant[36] Foreign Exchange Impact - The company estimates an adverse foreign exchange impact of approximately -3% to -4% (-$65 million to -$85 million) on Adjusted Cash Receipts[10, 58]